BioNTech was founded in 2008 on the understanding that every cancer patient’s tumor is unique and therefore each patient’s treatment should be individualized. It is our goal to develop novel therapies for cancer and other serious diseases. As we prove the value of our approach in the clinic, we will continue to build the partnerships, manufacturing and team required to bring individualized treatments to patients worldwide. With roots in Mainz, Germany, we are driven to become the leading global biotechnology company for individualized cancer medicine. The team in Martinsried, which joined BioNTech in 2016, focuses on small molecules therapeutics. The product candidate BNT411, a chemically synthesized TLR7 agonist, is the first candidate being developed in Martinsried and just having entered clinical Phase 1.

We are pioneers in personalised immunotherapies, committed to revolutionising patient care. For decades, we have been combining groundbreaking immunology research with modern therapeutic platforms and bioinformatics tools to develop personalized treatments for cancer and other diseases. We believe that there is a better way to treat cancer. The interaction between cancer and the immune system is influenced by various patient-specific, tumor-specific, and environmental factors. This complex interplay affects the disease progression of each patient individually and guides the selection of the most appropriate treatment.